Publication:
Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable >= Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Thumbnail Image

Date

2019

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

CIG MEDIA GROUP, LP

Research Projects

Organizational Units

Journal Issue

Abstract

Description

Keywords

elotuzumab, immunomodulatory drugs, Multiple myeloma

Citation

URI

https://hdl.handle.net/11424/222264

Collections

Araştırma Çıktıları

Endorsement

Review

Supplemented By

Referenced By